fda tirzepatide compound approval Compounded Semaglutide & 2025: Safe Use Guide Oral Tirzepatide Pill: FDA-Approved Options

Indias obesity drug market is heading into a pivotal phase as blockbuster GLP-1 therapies gain traction and patent expiries approach

In the published literature it is studied for post-meal glycemic control, appetite suppression and body-weight reduction , and it is the active molecule in the FDA-approved medicine Symlin, cleared in 2005 as an adjunct to mealtime insulin [1]

Here is the current outlook: Brand-Name Dominance: Currently, all available GLP-1s, both oral and injectable, are brand-name drugs protected by patents

GLP-1s may help quiet food noise Although food addiction is not formally recognized in the DSM-5, many clinicians observe compulsive eating behaviorsparticularly with ultra-processed foods high in sugar, salt, and fat